Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
Conditions
Metastatic Colorectal Cancer · Metastatic Gastroesophageal Adenocarcinoma · DPD Deficiency
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
CHU Amiens, Amiens, France
Contact: Study coordinator (Vincent HAUTEFEUILLE, MD)Institut de Cancérologie de l'Ouest, Angers, France
Contact: Study coordinator (Victor SIMMET, MD)Institut du Cancer d'Avignon, Avignon, France
CHU Jean Minjoz, Besançon, France
Centre Hospitalier de Cholet, Cholet, France
Centre Georges François Leclerc, Dijon, France
Hôpital Privé Jean Mermoz, Lyon, France
Institut Régional du Cancer de Montpellier - ICM Val d'Aurelle, Montpellier, France
Contact: Study coordinator (Emmanuelle SAMALIN, MD)Hôpital Saint Louis, Paris, France
Hôpital Saint Antoine, Paris, France
Contact: Study coordinator (Daniel LOPEZ, MD)Hôpital Cochin, Paris, France
Hôpital des Diaconesses Croix Saint Simon, Paris, France
Hospices Civils de Lyon, Pierre-Bénite, France
CHU de Poitiers, Poitiers, France
CHU de REIMS, Reims, France
Institut Godinot, Reims, France
Contact: Study coordinator (Damien BOTSEN, MD)Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France
CHU Saint-Etienne, Saint-Priest-en-Jarez, France
CH de Saint-Malo, St-Malo, France
Hôpital Nord Franche-Comté / Site du Mittan, Trévenans, France
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
Study leads
Emmanuelle SAMALIN, MD
Principal Investigator
Institut du Cancer de Montepllier